AIBullisharXiv – CS AI · 3d ago6/10
🧠A new framework argues that AI in biomedicine is transitioning from predictive systems based on historical data to interventional intelligence that can model biological responses to novel therapies. The shift reflects a fundamental architectural limitation: traditional AI cannot reason about unseen interventions, making disease-level models that simulate outcomes under perturbation essential for clinical decision-making.
AIBullisharXiv – CS AI · 3d ago6/10
🧠Researchers introduce ProtLiD², a discrete diffusion model that co-designs protein sequences and structures while conditioning on ligand information, achieving significant improvements in fold confidence and ligand-binding accuracy compared to existing methods. The model demonstrates practical advantages in both whole-protein and active-site pocket design tasks.
🏢 Meta
AIBullishCrypto Briefing · 3d ago6/10
🧠Biohub has launched an AI toolkit that democratizes drug discovery by enabling smaller biotech firms to access advanced protein design and AI-powered research capabilities previously available only to large pharmaceutical companies. This development has the potential to reshape the biotech industry by lowering barriers to entry and accelerating innovation across the sector.
AINeutralFortune Crypto · 3d ago6/10
🧠Sanofi is developing proprietary AI tools and workflows instead of purchasing off-the-shelf agentic AI products from SaaS vendors, positioning itself to gain competitive advantages in pharmaceutical development. This strategic shift reflects growing pharmaceutical interest in building custom AI capabilities tailored to specific industry needs rather than relying on generic enterprise solutions.
AINeutralarXiv – CS AI · 4d ago6/10
🧠Researchers introduce SCENE, a multi-agent AI framework that transforms general biomedical knowledge into specific, evidence-supported hypotheses grounded in experimental data. The system successfully identifies patient subgroups with different treatment responses in clinical trials and context-specific biological responses in genomic studies, bridging the gap between broad theoretical knowledge and actionable dataset-specific insights.
AIBullisharXiv – CS AI · 4d ago6/10
🧠Researchers introduce Periodic-TDL, a deep learning framework using topological data analysis to predict polymer properties more accurately than existing models. The approach captures many-body interactions across polymer chains and has been validated against experimental data from newly synthesized polymers, demonstrating practical utility in accelerating polymer discovery.
AINeutralarXiv – CS AI · 4d ago6/10
🧠Researchers introduce TriProRep, a protein representation learning method that jointly models amino acid identity, backbone geometry, and full-atom geometry to improve protein structure prediction. The new approach outperforms sequence-only and prior structure-aware models across multiple benchmarks including homodimer co-folding and monomer structure prediction tasks.
AINeutralarXiv – CS AI · 4d ago6/10
🧠Researchers introduce PolyFusionAgent, a multimodal AI framework combining a foundation model (PolyFusion) with an autonomous design agent (PolyAgent) for polymer discovery. The system integrates multiple polymer representations into a shared latent space to predict properties and generate novel structures, while grounding predictions in scientific literature for actionable design decisions.
AIBullishMIT News – AI · May 206/10
🧠Connor Coley is advancing machine learning applications in chemistry to accelerate drug discovery and compound design. This work represents a convergence of AI with pharmaceutical research, enabling computational models to understand and predict chemical behavior more effectively than traditional methods.
AIBullishGoogle DeepMind Blog · May 166/10
🧠Calico Life Sciences has implemented Co-Scientist, an AI tool designed to aggregate dispersed research findings and identify new research directions in aging studies. This application demonstrates how AI systems can accelerate scientific discovery by synthesizing complex datasets across multiple studies.
AINeutralGoogle DeepMind Blog · May 166/10
🧠Stanford researchers are leveraging AI tools called Co-Scientist to accelerate drug discovery for liver fibrosis treatment by identifying existing medicines that could be repurposed for this chronic liver disease. This approach demonstrates how artificial intelligence can streamline the pharmaceutical research process and potentially bring therapies to market faster.
AINeutralarXiv – CS AI · May 126/10
🧠Researchers propose SMER-Opt, a novel approach to molecular optimization that combines a single-step edit response predictor with multi-step planning via tree search. The method addresses the challenge of editing molecules for desired properties by treating molecular edits as discrete actions guided by chemical feasibility rules, reducing dependence on external oracles and improving data efficiency.
AINeutralarXiv – CS AI · May 126/10
🧠Researchers introduce TESSERA, a neuro-symbolic framework that combines Large Language Models with Monte Carlo Tree Search to extract multi-step explanations from knowledge graphs, specifically for drug-disease mechanism discovery. The system uses LLMs for local judgments rather than autonomous generation, enforcing structural constraints through knowledge graphs while employing MCTS for principled credit assignment across extended reasoning chains.
AINeutralarXiv – CS AI · May 116/10
🧠Researchers introduce MORetro*, a multi-objective optimization algorithm for computer-aided synthesis planning that generates Pareto-optimal routes balancing cost, sustainability, toxicity, and yield. This approach moves beyond single-route solutions to provide chemists with practical trade-off alternatives aligned with real-world industrial decision-making.
AIBullisharXiv – CS AI · May 116/10
🧠Researchers have developed a novel discrete diffusion model that improves computational antibody design by using germline sequences as an anchor point rather than masked tokens, reducing memorization of genetic patterns and enabling better conditional generation of antibodies with specific therapeutic properties like improved binding affinity.
AINeutralarXiv – CS AI · May 116/10
🧠Researchers have developed NaFM, a foundation model pretrained specifically for natural products using contrastive and masked graph learning objectives. The model achieves state-of-the-art results across drug discovery tasks including taxonomy classification and virtual screening, addressing limitations in existing deep learning approaches that lack generalizability for natural product research.
AIBullisharXiv – CS AI · May 76/10
🧠Gosset, a curated AI platform for pharmaceutical asset discovery, outperforms leading frontier LLMs (Claude, GPT-5.5, Gemini, Perplexity) by 3.2x on drug discovery queries, achieving perfect precision and complete recall on niche oncology and immunology targets. The research demonstrates that specialized, annotated databases significantly outperform general-purpose models with web search for domain-specific tasks.
🏢 Perplexity🧠 GPT-5🧠 Claude
AINeutralDecrypt – AI · Apr 186/10
🧠OpenAI has released GPT-Rosalind, a specialized AI model designed specifically for drug discovery and life sciences applications that can significantly accelerate research timelines. However, the model's access is restricted and not available to the general public, limiting its immediate impact to institutional researchers and pharmaceutical companies.
🏢 OpenAI
AINeutralarXiv – CS AI · Mar 166/10
🧠Researchers introduce Budget-Sensitive Discovery Score (BSDS), a formally verified framework for evaluating AI-guided scientific candidate selection under budget constraints. Testing on drug discovery datasets reveals that simple random forest models outperform large language models, with LLMs providing no marginal value over existing trained classifiers.
AIBearisharXiv – CS AI · Mar 96/10
🧠A comprehensive evaluation of Boltz-2, an AI-based drug discovery tool, reveals significant limitations in predicting protein-ligand binding structures and affinities. The study found only weak correlations with physics-based methods and concluded that while useful for initial screening, Boltz-2 lacks the precision required for reliable drug lead identification.
AIBullisharXiv – CS AI · Mar 36/108
🧠Researchers introduce MicroVerse, a specialized AI video generation model for microscale biological simulations, addressing limitations of current video generation models in scientific applications. The work includes MicroWorldBench benchmark and MicroSim-10K dataset, targeting biomedical applications like drug discovery and educational visualization.
AIBullisharXiv – CS AI · Mar 37/107
🧠Researchers introduce MERA (Multimodal Mixture-of-Experts with Retrieval Augmentation), a new AI framework for protein active site identification that addresses challenges in drug discovery. The system achieves 90% AUPRC performance on active site prediction through hierarchical multi-expert retrieval and reliability-aware fusion strategies.
AIBullisharXiv – CS AI · Mar 36/107
🧠Researchers developed a pharmacology knowledge graph for drug repurposing and found that removing chemical structure representations improved performance while dramatically reducing computational requirements. The study showed that drug behavior can be accurately predicted using only target protein information and network topology, with larger datasets proving more valuable than complex models.
AIBullisharXiv – CS AI · Mar 37/107
🧠Researchers introduce DeMol, a new dual-graph framework for molecular property prediction that explicitly models both atoms and chemical bonds to achieve superior accuracy. The approach addresses limitations of conventional atom-centric models by incorporating bond-level phenomena like resonance and stereoselectivity, establishing new state-of-the-art results across multiple benchmarks.
$ATOM
AIBullisharXiv – CS AI · Mar 37/106
🧠Researchers introduce MultiPUFFIN, a multimodal AI foundation model that predicts molecular properties for drug discovery and materials science. The model combines multiple data types and thermodynamic principles to achieve superior performance while using 2000x fewer training molecules than existing models like ChemBERTa-2.
